<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-158942" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Topical Steroid Withdrawal (Red Skin Syndrome)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mohta</surname>
            <given-names>Alpana</given-names>
          </name>
          <aff>Rajasthan University of Health Sciences, Jaipur, Rajasthan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sathe</surname>
            <given-names>Nishad C.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Alpana Mohta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Nishad Sathe declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>5</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-158942.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Topical corticosteroid withdrawal, also known as red skin syndrome or topical steroid addiction, is a drug-related dermatosis characterized by burning, itching, and erythema following the sudden termination of medium- to high-potency topical corticosteroids after prolonged use (typically at least&#x000a0;after&#x000a0;3&#x000a0;months of use).<xref ref-type="bibr" rid="article-158942.r1">[1]</xref><xref ref-type="bibr" rid="article-158942.r2">[2]</xref>&#x000a0;The syndrome is a form of tachyphylaxis and rebound vasodilation with skin barrier dysfunction.&#x000a0;Topical corticosteroid withdrawal most frequently affects the face and scrotum. However, every part of the body can be involved.<xref ref-type="bibr" rid="article-158942.r3">[3]</xref></p>
      </sec>
      <sec id="article-158942.s2" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of topical corticosteroid withdrawal remains inadequately defined, but&#x000a0;the&#x000a0;condition typically manifests following the application of medium-to-high-potency fluorinated&#x000a0;topical corticosteroids belonging to class I, II, and III for more than&#x000a0;12 weeks. The withdrawal less frequently occurs with short-term use of topical corticosteroids or those classified as low-potency topical corticosteroids.<xref ref-type="bibr" rid="article-158942.r4">[4]</xref>&#x000a0;As a type of drug addiction emerging from the inappropriate, excessive use of topical corticosteroids, the&#x000a0;reaction&#x000a0;occurs when the topical drug is used without supervision for an extended time, without a prescription, or when applied&#x000a0;for&#x000a0;unrecognized indications (eg, acne vulgaris). For example,&#x000a0;use in high potency in age groups (like children and older adults) or on unsuitable body areas like the face and scrotum&#x000a0;is not indicated.<xref ref-type="bibr" rid="article-158942.r5">[5]</xref>&#x000a0;Continual topical corticosteroid use creates withdrawal or rebound symptoms when the drug is discontinued, leading the patient back to using topical corticosteroids and making discontinuing the medication difficult.<xref ref-type="bibr" rid="article-158942.r6">[6]</xref></p>
      </sec>
      <sec id="article-158942.s3" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Topical corticosteroid withdrawal&#x000a0;is seen more commonly in women than men and in patients older than 18.<xref ref-type="bibr" rid="article-158942.r7">[7]</xref>&#x000a0;Most cases&#x000a0;involve patients using topical corticosteroids without supervision for atopic dermatitis, contact dermatitis, or dermatophytosis. The recent surge in incidence&#x000a0;is attributed&#x000a0;to the escalating&#x000a0;use of&#x000a0;topical corticosteroids on the skin. Additionally, unsupervised usage of topical corticosteroids for skin conditions, which deviates from established guidelines regarding the quantity, frequency, and duration of topical corticosteroid usage, and unscrupulous products containing corticosteroids are&#x000a0;important&#x000a0;causes.</p>
        <p>Moreover, several topical corticosteroids are readily available over the counter in many parts of the world, incentivizing their use without professional observation and monitoring.<xref ref-type="bibr" rid="article-158942.r8">[8]</xref>&#x000a0;Patients may use them based on recommendations from friends, neighbors, and relatives, often without consulting medical professionals.<xref ref-type="bibr" rid="article-158942.r9">[9]</xref>&#x000a0;Additionally,&#x000a0;a&#x000a0;considerable portion of the population may use steroids&#x000a0;for skin lightening. For instance, the modified Kligman formula includes mometasone, which patients may not be aware of.<xref ref-type="bibr" rid="article-158942.r10">[10]</xref></p>
      </sec>
      <sec id="article-158942.s4" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The pathogenesis of topical corticosteroid withdrawal involves multiple factors, including the vasoconstrictive effects of topical corticosteroids and potential barrier dysfunction, particularly in patients with atopic dermatitis. Proposed hypotheses encompass tachyphylaxis, dysregulation of glucocorticoid receptor function, and rebound vasodilation, culminating in initiating a cytokine cascade. These clinical features are frequently associated with the withdrawal of corticosteroids.<xref ref-type="bibr" rid="article-158942.r11">[11]</xref><xref ref-type="bibr" rid="article-158942.r12">[12]</xref>&#x000a0;The prolonged use of systemic steroids is known to suppress the production of cortisol from the adrenal glands. Since skin also produces cortisol, the extended application of topical corticosteroids, especially in patients with barrier dysfunction, suppresses cortisol production in the skin, leading to impaired immunity and inflammatory response.<xref ref-type="bibr" rid="article-158942.r13">[13]</xref></p>
        <p>One hypothesis suggests topical corticosteroids may reduce nitric oxide production, diminishing vasodilation. Consequently, upon discontinuing topical corticosteroids, the levels of nitrous oxide may rise, resulting in rebound vasodilation and erythema.&#x000a0;This phenomenon&#x000a0;may&#x000a0;partially&#x000a0;account&#x000a0;for the characteristic bright red, confluent erythema associated with topical corticosteroid withdrawal, colloquially referred to as red skin syndrome.&#x000a0;Furthermore,&#x000a0;patients with&#x000a0;atopic dermatitis might exhibit elevated baseline serum nitrous oxide levels, offering a speculative explanation for the occurrence of topical corticosteroid withdrawal in this patient population.<xref ref-type="bibr" rid="article-158942.r10">[10]</xref></p>
        <p>Another plausible mechanism for topical corticosteroid withdrawal in&#x000a0;patients with atopic dermatitis relates to barrier dysfunction. Patients with&#x000a0;atopic dermatitis inherently have&#x000a0;compromised skin barriers, a condition that can&#x000a0;be exacerbated&#x000a0;by topical corticosteroid usage and subsequent withdrawal. Notably, mouse studies have indicated that&#x000a0;topical corticosteroid cessation leads to increased transepidermal water loss and the upregulation of inflammatory cytokines. Given the preexisting skin barrier dysfunction in patients with atopic dermatitis, the induction of a cytokine cascade&#x000a0;may occur&#x000a0;when discontinuing topical corticosteroids, which contributes to the development of topical corticosteroid withdrawal.<xref ref-type="bibr" rid="article-158942.r14">[14]</xref></p>
      </sec>
      <sec id="article-158942.s5" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Histological examination lacks diagnostic value for topical corticosteroid withdrawal due to&#x000a0;the nonspecific features. In the erythematoedematous variant of topical corticosteroid withdrawal, the most frequent histopathological characteristics observed included epidermal atrophy, spongiosis,&#x000a0;hypogranulosis, a plethora of enlarged blood vessels within the dermal layer, scant perivascular cellular accumulation, prominently enlarged sebaceous structures encircled by inflammatory cells, and collagen deterioration. In a report of 41 patients with topical corticosteroid withdrawal, 36 cases demonstrated histopathological signs indicative of persistent eczema compounded by steroid-induced rosacea-like alterations, while 5 cases exhibited solely chronic eczematous traits.<xref ref-type="bibr" rid="article-158942.r15">[15]</xref>&#x000a0;In contrast, the papulopustular subtype&#x000a0;is characterized&#x000a0;by histological features akin to rosacea, including infiltrates around hair follicles or of a granulomatous nature comprising neutrophils and lymphocytes, expanded blood vessels in the dermal region, and a breakdown of collagen fibers.<xref ref-type="bibr" rid="article-158942.r16">[16]</xref><xref ref-type="bibr" rid="article-158942.r17">[17]</xref></p>
      </sec>
      <sec id="article-158942.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The most common symptoms of topical corticosteroid withdrawal are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Painful skin</p>
          </list-item>
          <list-item>
            <p>Burning</p>
          </list-item>
          <list-item>
            <p>Erythema</p>
          </list-item>
          <list-item>
            <p>Desquamation, exfoliation, or the detachment of skin layers (often manifesting as flaking, shedding, or peeling, with widespread skin involvement)</p>
          </list-item>
          <list-item>
            <p>Edema</p>
          </list-item>
          <list-item>
            <p>Paresthesia</p>
          </list-item>
          <list-item>
            <p>Atrophic changes such as skin thinning and wrinkling</p>
          </list-item>
          <list-item>
            <p>Exudative, purulent papules</p>
          </list-item>
          <list-item>
            <p>Steroid-induced dermatitis</p>
          </list-item>
          <list-item>
            <p>Papules and nodules</p>
          </list-item>
          <list-item>
            <p>Pain</p>
          </list-item>
          <list-item>
            <p>Sleep disturbances</p>
          </list-item>
          <list-item>
            <p>Alopecia</p>
          </list-item>
          <list-item>
            <p>Tremors or shivering</p>
          </list-item>
          <list-item>
            <p>Overwhelming fatigue</p>
          </list-item>
          <list-item>
            <p>Mood alterations, including depression</p>
          </list-item>
        </list>
        <p>Erythema and skin pain or burning are the&#x000a0;2&#x000a0;most consistent clinical features of topical corticosteroid withdrawal in all patients. Erythema may manifest within days to weeks after discontinuing topical corticosteroids, commonly originating from the initial eczematous site but spreading to regions not previously affected by eczema. The burning sensation and heightened pain sensitivity indicate potential neurogenic inflammation with notable similarities to erythromelalgia.<xref ref-type="bibr" rid="article-158942.r14">[14]</xref></p>
        <p>Typically&#x000a0;2&#x000a0;main variants of&#x000a0;topical corticosteroid withdrawal, including the erythematoedematous and papulopustular subtypes. The erythematoedematous subtype&#x000a0;is&#x000a0;frequently observed among patients with chronic atopic dermatitis and is marked by burning, redness, swelling, and scaling sensations.<xref ref-type="bibr" rid="article-158942.r18">[18]</xref>&#x000a0;Meanwhile, the&#x000a0;papulopustular subtype is&#x000a0;often seen following steroid use for cosmetic reasons or pigmentation alterations, exhibiting papules, pustules, and redness. Unlike the erythematoedematous subtype, this variant typically lacks burning, stinging, or notable swelling.<xref ref-type="bibr" rid="article-158942.r17">[17]</xref></p>
        <p>Other features or signs may&#x000a0;be observed, including:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Red face syndrome&#x000a0;</bold>presents as an outbreak, clinically similar to steroid-induced rosacea or iatrosacea. This condition&#x000a0;is marked&#x000a0;by uniform inflammatory papules and pustules in the centrofacial and periorificial (perioral and periocular) regions. The face appears fiery red, scaly, and covered with papules. Without treatment,&#x000a0;the syndrome can lead to irreversible skin thinning and telangiectasia.</p>
          </list-item>
          <list-item>
            <p><bold>Red&#x000a0;sleeve sign</bold>&#x000a0;is a rebound rash on the upper or lower extremities, stopping sharply at the border where the limb's back and front (or plantar) sides meet. The skin on palms and soles usually remains unaffected except in the most severe cases of topical corticosteroid withdrawal.</p>
          </list-item>
          <list-item>
            <p><bold>Headlight sign</bold>&#x000a0;refers to a clear nose and skin around the mouth amidst a red facial complexion. The redness typically halts midway through the cheek, leaving normal skin from this point to the ears.</p>
          </list-item>
          <list-item>
            <p><bold>Elephant wrinkles&#x000a0;</bold>are characterized by thickened skin and less elastic skin, seen on the front of the knees and outer sides of the elbows. The resolution of this condition may take several months.<xref ref-type="bibr" rid="article-158942.r19">[19]</xref><xref ref-type="bibr" rid="article-158942.r20">[20]</xref><xref ref-type="bibr" rid="article-158942.r21">[21]</xref></p>
          </list-item>
        </list>
        <p>Other features include skin sensitivity, desquamation, exfoliation, flaking, shedding, peeling, and erythoderma. Steroid dermatitis, alopecia, purulent skin infections, and flare-ups of preexisting dermatoses like dermatophytosis, eczema or psoriasis, alopecia or excessive hair growth, and skin atrophy.&#x000a0;Swelling around the eyelids or ankles may be seen. In more pigmented skin, alterations might involve darker or grey tones rather than the typical redness. The clinical features also tend to extend beyond the skin and lead to systemic symptoms like tremors, shivering, lymphadenopathy, overwhelming fatigue, sleep disturbances, mood alterations, and depression.<xref ref-type="bibr" rid="article-158942.r22">[22]</xref></p>
      </sec>
      <sec id="article-158942.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The diagnostic criteria for topical corticosteroid withdrawal is unclear,&#x000a0;but recent literature has identified some key features, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>History of prolonged and frequent use of topical steroids on the initial eruption area or face and genitalia</p>
          </list-item>
          <list-item>
            <p>History of atopy,&#x000a0;particularly&#x000a0;atopic dermatitis</p>
          </list-item>
          <list-item>
            <p>Previous use of oral prednisone for skin symptoms</p>
          </list-item>
          <list-item>
            <p>The rapid development of skin burning or itchiness with widespread redness (erythema) days to weeks after stopping topical steroids, along with oozing, crusting, and exfoliation</p>
          </list-item>
        </list>
        <p>One of the primary challenges involves distinguishing between the skin reaction resulting from discontinuing topical corticosteroids and a deterioration in the underlying skin condition for which the steroids&#x000a0;were prescribed.&#x000a0;Patch testing&#x000a0;is beneficial in ruling out contact dermatitis caused by topical corticosteroids, cream components, or other topically applied agents (eg, emollients). However, this&#x000a0;could be challenging if insufficient areas of normal skin are available for testing.<xref ref-type="bibr" rid="article-158942.r12">[12]</xref><xref ref-type="bibr" rid="article-158942.r23">[23]</xref><xref ref-type="bibr" rid="article-158942.r24">[24]</xref></p>
      </sec>
      <sec id="article-158942.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Topical corticosteroid withdrawal poses a challenge in clinical management due to the absence of definitive treatment protocols. Therapeutic interventions are varied and demonstrate limited evidence in reducing the duration of the withdrawal symptoms. General therapeutic approaches include the application of emollients and moisturizers coupled with adjunct modalities such as cold compresses, ice, and gabapentin to alleviate burning pain. Antihistamines and doxepin&#x000a0;are utilized&#x000a0;to address pruritus, while simple analgesics may mitigate the burning pain. Psychological support plays a crucial role in managing the psychosocial impact of topical corticosteroid withdrawal.</p>
        <p>For more severe symptoms, gabapentin, phototherapy, or immunosuppressants might&#x000a0;be recommended. Limited use of sleeping aids and anxiolytics&#x000a0;is appropriate in certain situations.<xref ref-type="bibr" rid="article-158942.r17">[17]</xref>&#x000a0;Specific strategies involve the cessation of topical corticosteroids as the primary intervention, necessitating vigilant monitoring for potential rebound reactions. The method of discontinuation, abrupt cessation versus tapering, remains a matter of debate. Some advocate for a tapering dose of oral corticosteroids, while others may consider a low-potency topical corticosteroid with minimal allergenic potential. For patients with the papulopustular type of topical corticosteroid withdrawal, tetracycline antibiotics and calcineurin inhibitors have reportedly been effective. In cases of atopic dermatitis,&#x000a0;dupilumab&#x000a0;may be considered.<xref ref-type="bibr" rid="article-158942.r10">[10]</xref><xref ref-type="bibr" rid="article-158942.r22">[22]</xref><xref ref-type="bibr" rid="article-158942.r25">[25]</xref></p>
      </sec>
      <sec id="article-158942.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Identifying topical corticosteroid withdrawal requires a meticulous approach to differential diagnosis within dermatological conditions. Considerations involve various skin disorders presenting with similar manifestations, notably including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Contact dermatitis</p>
          </list-item>
          <list-item>
            <p>Atopic dermatitis</p>
          </list-item>
          <list-item>
            <p>Rosacea</p>
          </list-item>
          <list-item>
            <p>Cutaneous T-cell lymphoma</p>
          </list-item>
          <list-item>
            <p>Psoriasis</p>
          </list-item>
          <list-item>
            <p>Red scrotum syndrome</p>
          </list-item>
        </list>
        <p>Contact dermatitis mimics topical corticosteroid withdrawal symptoms, featuring erythema, edema, and vesicles. Atopic dermatitis flares might exhibit similar signs of eczematous dermatitis, while rosacea could manifest with flushing and papulopustular lesions resembling steroid withdrawal symptoms. Cutaneous T-cell lymphoma typically presents as persistent or progressive patches, plaques, or nodules.&#x000a0;Psoriasis may show red, scaly plaques, occasionally mistaken for symptoms akin to topical corticosteroid withdrawal.<xref ref-type="bibr" rid="article-158942.r17">[17]</xref>&#x000a0;Another clinical&#x000a0;condition routinely confused with topical corticosteroid withdrawal&#x000a0;is red scrotum syndrome.&#x000a0;The syndrome&#x000a0;is marked&#x000a0;by a persistent reddening of the front part of the scrotum, which can also affect the base of the penis. The disease&#x000a0;is characterized&#x000a0;by symptoms such as itching, burning, and discomfort. However, the etiology might not always be steroid-induced, with most cases being idiopathic or neurological.<xref ref-type="bibr" rid="article-158942.r26">[26]</xref>&#x000a0;A thorough evaluation should&#x000a0;be performed to&#x000a0;rule out these alternate diagnoses.</p>
      </sec>
      <sec id="article-158942.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>No definitive treatments exist to distinctly shorten the resolution period for topical corticosteroid withdrawal. However, complete recovery may take anywhere between 6 to 18 months. In a minority of cases, topical corticosteroid withdrawal may present a prolonged course extending up to&#x000a0;5 years following cessation.<xref ref-type="bibr" rid="article-158942.r27">[27]</xref><xref ref-type="bibr" rid="article-158942.r28">[28]</xref><xref ref-type="bibr" rid="article-158942.r29">[29]</xref></p>
      </sec>
      <sec id="article-158942.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Many&#x000a0;complications may occur if topical corticosteroid withdrawal&#x000a0;is not appropriately addressed. These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Severe pruritus and sleep disturbances: Patients withdrawing from topical corticosteroids often&#x000a0;have&#x000a0;intense itching (pruritus), which can severely disrupt sleep.</p>
          </list-item>
          <list-item>
            <p>Tachyphylaxis: This&#x000a0;refers to the diminished response to topical steroids over time, often seen in conditions like psoriasis and atopic dermatitis.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Exacerbation of original skin conditions or rebound phenomenon: Abrupt discontinuation of topical corticosteroid therapy can worsen initial skin disorders like atopic dermatitis, resulting in increased flare-ups.</p>
          </list-item>
          <list-item>
            <p>Secondary cutaneous infections: Withdrawal from these medications can compromise the skin barrier, making patients more susceptible to secondary skin infections.</p>
          </list-item>
          <list-item>
            <p>Skin atrophy: This is the most frequently occurring issue. Topical steroids cause thinning in the epidermis and dermis, leading to skin that appears lax, wrinkled, and transparent. Over time, the atrophy&#x000a0;can result in reduced cellular layers in the skin, hypopigmentation, and visible veins.</p>
          </list-item>
          <list-item>
            <p>Striae: Striae distinct from those caused by weight gain or pregnancy can develop.</p>
          </list-item>
          <list-item>
            <p>Contact allergy: Steroid withdrawal can lead to contact hypersensitivity, which&#x000a0;may worsen or prolong existing skin conditions.</p>
          </list-item>
          <list-item>
            <p>Rosacea: Older&#x000a0;women may experience topical steroid-induced rosacea, marked by papules and pustules, which can worsen with withdrawal.</p>
          </list-item>
          <list-item>
            <p>Pigmentary changes: Both hyperpigmentation and hypopigmentation can occur, with the latter more noticeable in patients with Fitzpatrick skin types IV, V, or VI.<xref ref-type="bibr" rid="article-158942.r30">[30]</xref><xref ref-type="bibr" rid="article-158942.r31">[31]</xref><xref ref-type="bibr" rid="article-158942.r32">[32]</xref><xref ref-type="bibr" rid="article-158942.r33">[33]</xref><xref ref-type="bibr" rid="article-158942.r34">[34]</xref><xref ref-type="bibr" rid="article-158942.r35">[35]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-158942.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>To prevent topical corticosteroid withdrawal, patient education, and careful prescribing are critical.&#x000a0;Clinicians should inform patients about the risks of long-term or unsupervised use of topical corticosteroids, including topical corticosteroid withdrawal symptoms like redness, burning, and peeling skin.&#x000a0;Teaching the correct application methods and&#x000a0;avoiding using solid steroids on delicate skin areas is crucial, particularly on sensitive skin areas like the face and intertriginous zones. Alternatives to topical corticosteroids should&#x000a0;be considered&#x000a0;in all patient cases, and gradually tapering off is essential compared with abrupt discontinuation, particularly if the medication has&#x000a0;been used&#x000a0;for an extended period. The appropriate use of topical corticosteroids with proper professional observation, guidance, and monitoring should be encouraged in all situations.</p>
      </sec>
      <sec id="article-158942.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Minimize topical corticosteroid usage frequency and strength&#x000a0;when skin inflammations subside to prevent recurring daily application. Avoid prolonged use of potent topical corticosteroids, particularly on the face. Limit the duration of continuous corticosteroid treatment, aiming for periods shorter than&#x000a0;2&#x000a0;weeks. However, specific conditions like lichen sclerosus might necessitate therapy over&#x000a0;4&#x000a0;weeks to optimize outcomes&#x02014;transition from daily to twice-weekly application after 2 to 4 weeks of initial steroid use.&#x000a0;While the risk of topical corticosteroid withdrawal may occur,&#x000a0;this should not impede the treatment of conditions like atopic dermatitis or psoriasis.</p>
      </sec>
      <sec id="article-158942.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=158942&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=158942">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/skin-problems-and-treatments/topical-steroid-withdrawal-red-skin-syndrome/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=158942">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/158942/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=158942">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-158942.s15">
        <title>References</title>
        <ref id="article-158942.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brookes</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Barlow</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mohandas</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bewley</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical steroid withdrawal: an emerging clinical problem.</article-title>
            <source>Clin Exp Dermatol</source>
            <year>2023</year>
            <month>Aug</month>
            <day>25</day>
            <volume>48</volume>
            <issue>9</issue>
            <fpage>1007</fpage>
            <page-range>1007-1011</page-range>
            <pub-id pub-id-type="pmid">37119282</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spergel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>DYM</given-names>
              </name>
            </person-group>
            <article-title>Topical steroid withdrawal syndrome: Should we worry?</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2023</year>
            <month>Jan</month>
            <volume>130</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <pub-id pub-id-type="pmid">36596614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lahiri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Coondoo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical Steroid Damaged/Dependent Face (TSDF): An Entity of Cutaneous Pharmacodependence.</article-title>
            <source>Indian J Dermatol</source>
            <year>2016</year>
            <season>May-Jun</season>
            <volume>61</volume>
            <issue>3</issue>
            <fpage>265</fpage>
            <page-range>265-72</page-range>
            <pub-id pub-id-type="pmid">27293246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chu</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>484</fpage>
            <page-range>484-90</page-range>
            <pub-id pub-id-type="pmid">17373975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saraswat</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lahiri</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chatterjee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Barua</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coondoo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mittal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Panda</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rajagopalan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abraham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Srinivas</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroid abuse on the face: a prospective, multicenter study of dermatology outpatients.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2011</year>
            <season>Mar-Apr</season>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>160</fpage>
            <page-range>160-6</page-range>
            <pub-id pub-id-type="pmid">21393945</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gust</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>SE</given-names>
              </name>
            </person-group>
            <article-title>The role of delayed-delayed corticosteroid contact dermatitis in topical steroid withdrawal.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>75</volume>
            <issue>4</issue>
            <fpage>e167</fpage>
            <pub-id pub-id-type="pmid">27646768</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cotter</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Burton</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Proctor</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moss</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Flohr</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Topical steroid withdrawal syndrome: time to bridge the gap.</article-title>
            <source>Br J Dermatol</source>
            <year>2022</year>
            <month>Nov</month>
            <volume>187</volume>
            <issue>5</issue>
            <fpage>780</fpage>
            <page-range>780-781</page-range>
            <pub-id pub-id-type="pmid">35833942</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Sales, status, prescriptions and regulatory problems with topical steroids in India.</article-title>
            <source>Indian J Dermatol Venereol Leprol</source>
            <year>2014</year>
            <season>May-Jun</season>
            <volume>80</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-3</page-range>
            <pub-id pub-id-type="pmid">24823396</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Qutob</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Alhusaini</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Aljarba</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Alzaid</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Aljahili</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Alzahrani</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Sharaf</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Alghamdi</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Alaryni</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Alammari</surname>
                <given-names>YM</given-names>
              </name>
              <name>
                <surname>Alanazi</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Faqihi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Al Harbi</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Alsolamy</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Hakami</surname>
                <given-names>OA</given-names>
              </name>
            </person-group>
            <article-title>Public Awareness Regarding Corticosteroid Use and Side Effects: A Cross-Sectional Study in Riyadh, Saudi Arabia.</article-title>
            <source>Healthcare (Basel)</source>
            <year>2023</year>
            <month>Oct</month>
            <day>16</day>
            <volume>11</volume>
            <issue>20</issue>
            <pub-id pub-id-type="pmid">37893821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arnold</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Treister</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lio</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: A retrospective case series.</article-title>
            <source>JAAD Case Rep</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>4</volume>
            <issue>9</issue>
            <fpage>860</fpage>
            <page-range>860-862</page-range>
            <pub-id pub-id-type="pmid">30306110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Uva</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pinheiro</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Antunes</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cruz</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Filipe</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of topical corticosteroids in psoriasis.</article-title>
            <source>Int J Endocrinol</source>
            <year>2012</year>
            <volume>2012</volume>
            <fpage>561018</fpage>
            <pub-id pub-id-type="pmid">23213332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Croxtall</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>van Hal</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Choudhury</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Gilroy</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Flower</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Different glucocorticoids vary in their genomic and non-genomic mechanism of action in A549 cells.</article-title>
            <source>Br J Pharmacol</source>
            <year>2002</year>
            <month>Jan</month>
            <volume>135</volume>
            <issue>2</issue>
            <fpage>511</fpage>
            <page-range>511-9</page-range>
            <pub-id pub-id-type="pmid">11815387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kao</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fluhr</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Hachem</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Crumrine</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Feingold</surname>
                <given-names>KR</given-names>
              </name>
            </person-group>
            <article-title>Short-term glucocorticoid treatment compromises both permeability barrier homeostasis and stratum corneum integrity: inhibition of epidermal lipid synthesis accounts for functional abnormalities.</article-title>
            <source>J Invest Dermatol</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>120</volume>
            <issue>3</issue>
            <fpage>456</fpage>
            <page-range>456-64</page-range>
            <pub-id pub-id-type="pmid">12603860</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Chandran</surname>
                <given-names>NS</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>Steroid Phobia: Is There a Basis? A Review of Topical Steroid Safety, Addiction and Withdrawal.</article-title>
            <source>Clin Drug Investig</source>
            <year>2021</year>
            <month>Oct</month>
            <volume>41</volume>
            <issue>10</issue>
            <fpage>835</fpage>
            <page-range>835-842</page-range>
            <pub-id pub-id-type="pmid">34409577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheary</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Steroid Withdrawal Effects Following Long-term Topical Corticosteroid Use.</article-title>
            <source>Dermatitis</source>
            <year>2018</year>
            <season>Jul/Aug</season>
            <volume>29</volume>
            <issue>4</issue>
            <fpage>213</fpage>
            <page-range>213-218</page-range>
            <pub-id pub-id-type="pmid">29923852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zalaudek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Di Stefani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ferrara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Argenziano</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Childhood granulomatous periorificial dermatitis: a controversial disease.</article-title>
            <source>J Dtsch Dermatol Ges</source>
            <year>2005</year>
            <month>Apr</month>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>252</fpage>
            <page-range>252-5</page-range>
            <pub-id pub-id-type="pmid">16370472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hwang</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lio</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroid withdrawal ('steroid addiction'): an update of a systematic review.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2022</year>
            <month>May</month>
            <volume>33</volume>
            <issue>3</issue>
            <fpage>1293</fpage>
            <page-range>1293-1298</page-range>
            <pub-id pub-id-type="pmid">33499686</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Narang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kumaran</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Dogra</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saikia</surname>
                <given-names>UN</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Red scrotum syndrome: idiopathic neurovascular phenomenon or steroid addiction?</article-title>
            <source>Sex Health</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>10</volume>
            <issue>5</issue>
            <fpage>452</fpage>
            <page-range>452-5</page-range>
            <pub-id pub-id-type="pmid">24028828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhat</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Manzoor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Qayoom</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Steroid-induced rosacea: a clinical study of 200 patients.</article-title>
            <source>Indian J Dermatol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>56</volume>
            <issue>1</issue>
            <fpage>30</fpage>
            <page-range>30-2</page-range>
            <pub-id pub-id-type="pmid">21572787</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapaport</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Corticosteroid addiction and withdrawal in the atopic: the red burning skin syndrome.</article-title>
            <source>Clin Dermatol</source>
            <year>2003</year>
            <season>May-Jun</season>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-14</page-range>
            <pub-id pub-id-type="pmid">12781438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheary</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Topical Steroid Withdrawal: A Case Series of 10 Children.</article-title>
            <source>Acta Derm Venereol</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>99</volume>
            <issue>6</issue>
            <fpage>551</fpage>
            <page-range>551-556</page-range>
            <pub-id pub-id-type="pmid">30734047</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kurban</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Red scrotum syndrome: An update on clinicopathologic features, pathogenesis, diagnosis, and management.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2022</year>
            <month>Sep</month>
            <volume>87</volume>
            <issue>3</issue>
            <fpage>614</fpage>
            <page-range>614-622</page-range>
            <pub-id pub-id-type="pmid">32497688</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>SY</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Steroid phobia among general users of topical steroids: a cross-sectional nationwide survey.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2019</year>
            <month>May</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>245</fpage>
            <page-range>245-250</page-range>
            <pub-id pub-id-type="pmid">30081700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tatu</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>TOPICAL STEROID INDUCED FACIAL ROSACEIFORM DERMATITIS.</article-title>
            <source>Acta Endocrinol (Buchar)</source>
            <year>2016</year>
            <season>Apr-Jun</season>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>232</fpage>
            <page-range>232-233</page-range>
            <pub-id pub-id-type="pmid">31149094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wollina</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Red scrotum syndrome.</article-title>
            <source>J Dermatol Case Rep</source>
            <year>2011</year>
            <month>Sep</month>
            <day>21</day>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>38</fpage>
            <page-range>38-41</page-range>
            <pub-id pub-id-type="pmid">22187577</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marshall</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Leung</surname>
                <given-names>DYM</given-names>
              </name>
              <name>
                <surname>Lack</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sindher</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ciaccio</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nadeau</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Brough</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Topical steroid withdrawal and atopic dermatitis.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2024</year>
            <month>Apr</month>
            <volume>132</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-425</page-range>
            <pub-id pub-id-type="pmid">38142858</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jain</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohapatra</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mohanty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jena</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Behera</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Study of Clinical Profile of Patients Presenting with Topical Steroid-Induced Facial Dermatosis to a Tertiary Care Hospital.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2020</year>
            <season>Mar-Apr</season>
            <volume>11</volume>
            <issue>2</issue>
            <fpage>208</fpage>
            <page-range>208-211</page-range>
            <pub-id pub-id-type="pmid">32477980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leyden</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Thew</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kligman</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>Steroid rosacea.</article-title>
            <source>Arch Dermatol</source>
            <year>1974</year>
            <month>Oct</month>
            <volume>110</volume>
            <issue>4</issue>
            <fpage>619</fpage>
            <page-range>619-22</page-range>
            <pub-id pub-id-type="pmid">4278287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rapaport</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rapaport</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Eyelid dermatitis to red face syndrome to cure: clinical experience in 100 cases.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>41</volume>
            <issue>3 Pt 1</issue>
            <fpage>435</fpage>
            <page-range>435-42</page-range>
            <pub-id pub-id-type="pmid">10459119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feschuk</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Topical steroid withdrawal syndrome in a mother and son: A case report.</article-title>
            <source>SAGE Open Med Case Rep</source>
            <year>2023</year>
            <volume>11</volume>
            <fpage>2050313X231164268</fpage>
            <pub-id pub-id-type="pmid">37051261</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Tachyphylaxis to topical corticosteroids: the more you use them, the less they work?</article-title>
            <source>Clin Dermatol</source>
            <year>2006</year>
            <season>May-Jun</season>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>229</fpage>
            <page-range>229-30; discussion 230</page-range>
            <pub-id pub-id-type="pmid">16714204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Coondoo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Phiske</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lahiri</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Side-effects of topical steroids: A long overdue revisit.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2014</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>416</fpage>
            <page-range>416-25</page-range>
            <pub-id pub-id-type="pmid">25396122</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hengge</surname>
                <given-names>UR</given-names>
              </name>
              <name>
                <surname>Ruzicka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Cork</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Adverse effects of topical glucocorticosteroids.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-15; quiz 16-8</page-range>
            <pub-id pub-id-type="pmid">16384751</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhossche</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hajar</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Topical corticosteroid withdrawal in a pediatric patient.</article-title>
            <source>JAAD Case Rep</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>3</volume>
            <issue>5</issue>
            <fpage>420</fpage>
            <page-range>420-421</page-range>
            <pub-id pub-id-type="pmid">28932784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-158942.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abraham</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roga</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Topical steroid-damaged skin.</article-title>
            <source>Indian J Dermatol</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>59</volume>
            <issue>5</issue>
            <fpage>456</fpage>
            <page-range>456-9</page-range>
            <pub-id pub-id-type="pmid">25284849</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
